Clinical review: The role of advanced glycation end products in progression and complications of diabetes.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review describing biological mechanisms without systematic review methodology or primary clinical data
PubMed 18182449 · doi:10.1210/jc.2007-1817
What was done
This narrative clinical review summarized the biochemical formation of advanced glycation end products (AGEs), their pathophysiological roles in diabetic complications, and therapeutic strategies targeting AGE formation, degradation, and receptor binding (such as RAGE).
What was found
The abstract reports no quantitative data or effect estimates. It details two main mechanistic pathways: direct cross-linking of long-lived proteins like collagen that enhances vascular stiffness, and interaction with receptors such as RAGE to stimulate oxidative stress and proinflammatory and prosclerotic cytokine release.
Why it matters
It provides a mechanistic overview of how advanced glycation end products contribute to vascular pathology in diabetes and identifies potential molecular targets for intervention.
Limits
As a non-systematic narrative review, it lacks formal literature search criteria, study quality assessment, and quantitative synthesis. The therapeutic interventions discussed are derived primarily from preclinical models without clinical outcome data in the abstract.
Cited by
- supports Chronically elevated blood glucose drives protein glycation, oxidative stress, and vascular inflammation, damaging blood vessels in the kidneys, retina, feet, coronary arteries, and carotid arteries.